Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 3/20 | 0.42 |
| ▸ | CASP7 | P55210 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634900 | 0.89 | KDM4E (0.45) | KMT2AMEN1ATMKDM4EALDH1A1 | |
| SCHEMBL635404 | 0.89 | PTGDR2 (0.39) | KMT2AMEN1LMNAABCC4PKM | |
| SCHEMBL634012 | 0.88 | KDM4E (0.40) | KMT2AMEN1LMNAABCC4PKM | |
| SCHEMBL634442 | 0.87 | L3MBTL1 (0.43) | KMT2AMEN1LMNAPABPC1ATM | |
| SCHEMBL632020 | 0.86 | CNR2 (0.39) | KMT2AMEN1PABPC1ATMKDM4E | |
| SCHEMBL21798655 | 0.85 | PDE10A (0.46) | KMT2AMEN1LMNAPABPC1ATM | |
| SCHEMBL30122318 | 0.84 | KDM4E (0.41) | KMT2AMEN1LMNAPABPC1ATM | |
| SCHEMBL634087 | 0.84 | KDM4E (0.41) | KMT2AMEN1LMNAPABPC1ATM | |
| SCHEMBL635605 | 0.83 | TNF (0.52) | — | |
| SCHEMBL5823899 | 0.83 | BRD4 (0.46) | KMT2AMEN1LMNAABCC4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | BAGULEY BRUCE CHARLES | 2009-06-18 | — | — | US | claimed |
| US-11046687-B2 | Polycyclic amide compound, preparation process and use thereof | HEBEI GRANDIOS PHARMA CO., LTD. | 2021-06-29 | — | — | US | disclosed |
| US-20200079771-A1 | Novel Polycyclic Amide Compound, Preparation Process And Use Thereof | HEBEI GRANDIOS PHARMA CO., LTD. (CN) | 2020-03-12 | — | — | US | disclosed |
| EP-1507778-B1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | UNIV TROBE (AU) | 2012-02-22 | — | — | EP | disclosed |
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | BAGULEY BRUCE CHARLES | 2009-06-18 | — | — | US | disclosed |
| US-7504507-B2 | Anti-tumour polycyclic carboxamides | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-03-17 | — | — | US | disclosed |
| US-20050245561-A1 | Anti-tumour polycyclic carboxamides | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156630-A1 | ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES | MKI67, MCL1, CCNI | KMT2A 436/4885MEN1 1279/4885LMNA 609/4885 |
| US-20200079771-A1 | Novel Polycyclic Amide Compound, Preparation Process And Use Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0, UACA | KMT2A 2396/4885MEN1 936/4885LMNA 2279/4885 |
| US-20050245561-A1 | Anti-tumour polycyclic carboxamides | MKI67, MCL1, CCNI | KMT2A 492/4885MEN1 1089/4885LMNA 537/4885 |
| US-11046687-B2 | Polycyclic amide compound, preparation process and use thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UACA, H1-0 | KMT2A 2477/4885MEN1 694/4885LMNA 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.